{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Neuronal Signal Pathway > Atracurium BesylateCAS：64228-81-5
Molecular Formula：C65H82N2O18S2
Molecular Weight：1243.48
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：White to off-white Solid
Qty：
Size：
| CAS | 64228-81-5 |
| Name | Atracurium Besylate |
| Molecular Formula | C65H82N2O18S2 |
| Molecular Weight | 1243.48 |
| Solubility | Soluble in Water/DMSO(Need ultrasonic) |
| Purity | ≥98% |
| Appearance | White to off-white Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| EC | EINECS 264-743-4 |
| MDL | MFCD00797403 |
| SMILES | C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C=C6)OC)OC)OC)OC)C.C1=CC=C(C=C1)S(=O)(=O)[O-].C1=CC=C(C=C1)S(=O)(=O)[O-] |
| InChIKey | XXZSQOVSEBAPGS-UHFFFAOYSA-L |
| InChI | InChI=1S/C53H72N2O12.2C6H6O3S/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6;2*7-10(8，9)6-4-2-1-3-5-6/h14-17，30-35，42-43H，11-13，18-29H2，1-10H3;2*1-5H，(H，7，8，9)/q+2;;/p-2 |
| PubChem CID | 47320 |
| Target Point | AChR |
| Passage | Neuronal Signaling |
| Background | It is an effective, competitive, non-depolarized neuromuscular blocking agent and an AChR receptor antagonist. |
| Biological Activity | Atracurium Besylate 是一种强效、竞争性、非去极化神经肌肉阻断剂，一种 AChR 受体拮抗剂，可引起支气管收缩和神经肌肉阻滞，可促进星形胶质细胞分化。[1-5] |
| Data Literature Source | [1]. Basta SJ，et al. Clinical pharmacology of atracurium besylate (BW 33A): a new non-depolarizing muscle relaxant. Anesth Analg. 1982 Sep;61(9):723-9. [2]. Levitt RC，et al. Genetic susceptibility to atracurium-induced bronchoconstriction. Am J Respir Crit Care Med. 1995 May;151(5):1537-42. [3]. Mayer B，et al. Inflammatory liver disease shortens atracurium-induced neuromuscular blockade in rats. Eur J Anaesthesiol. 2001 Sep;18(9):599-604. [4]. Spina R，et al. Atracurium Besylate and other neuromuscular blocking agents promote astroglial differentiation and deplete glioblastoma stem cells. Oncotarget. 2016 Jan 5;7(1):459-72. [5]. Nascimento DC，et al. Cellular mechanisms of atracurium-induced tetanic fade in the isolated rat muscle. Basic Clin Pharmacol Toxicol. 2004 Jul;95(1):9-14. |
| Unit | Bottle |
| Specification | 25mg 50mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
